Level Biotechnology Inc. (TPEX:3118)
31.75
+0.45 (1.44%)
Aug 26, 2026, 11:52 AM CST
Level Biotechnology Revenue
Level Biotechnology had revenue of 162.35M TWD in the quarter ending June 30, 2026, a decrease of -5.37%. This brings the company's revenue in the last twelve months to 709.37M, down -3.54% year-over-year. In the year 2025, Level Biotechnology had annual revenue of 736.59M with 0.72% growth.
Revenue (ttm)
709.37M
Revenue Growth
-3.54%
P/S Ratio
1.43
Revenue / Employee
5.54M
Employees
128
Market Cap
1.02B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 736.59M | 5.25M | 0.72% |
| Dec 31, 2024 | 731.35M | 70.74M | 10.71% |
| Dec 31, 2023 | 660.61M | 67.60M | 11.40% |
| Dec 31, 2022 | 593.01M | -84.27M | -12.44% |
| Dec 31, 2021 | 677.28M | 4.79M | 0.71% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Meribank Biotech | 408.48M |
| NeoCore Technology | 277.54M |
| TCI GENE | 251.39M |
| GeneReach Biotechnology | 238.08M |
| Lukas Biomedical | 170.01M |
| Enimmune | 53.45M |
| Holy Stone Healthcare | 47.51M |